Neurology:小剂量阿司匹林与颅内出血的相关性分析!

2017-11-02 xing.T MedSci原创

由此可见,低剂量阿司匹林与任何类型的ICB风险增加无关,但使用低剂量阿司匹林超过1年,其与SAH风险明显降低相关。

近日,神经病学领域权威取杂志Neurology上发表了一篇研究文章,研究人员通过一个以人群为基础的初级保健数据库来量化预防性使用低剂量阿司匹林个体颅内出血(ICBs)风险。

研究人员将新近服用小剂量阿司匹林(75-300mg;n=199079)年龄在40-84岁期间的患者以及按1:1匹配未服用小剂量阿司匹林患者随访(最长14年,平均5.4年)后确定的ICB的发生率,研究人员通过对患者病历或联系住院数据进行人工审核验证。研究人员计算了当前使用低剂量阿司匹林个体调整后的率比(RR)和95%可信区间(CI),对照组是不使用低剂量阿司匹林的个体。

研究人员发现有1611例患者发生ICB(n=743为脑出血[ICH],n=483为硬膜下血肿[SDH],以及n=385为蛛网膜下腔出血[SAH])。对于所有ICB 的RR(95%CI)为0.98(0.84-1.13),对于ICH 为0.98(0.80-1.20),对于SDH 为1.23(0.95-1.59)以及对于SAH为0.77(0.58-1.01)。没有观察到使用时间或剂量-反应的明显相关性。使用低剂量阿司匹林超过1年对于ICH的RRs(95%CI)为0.90(0.72-1.13),对于SDH 为1.20(0.91-1.57)以及对于SAH为0.69(0.50-0.94)。

由此可见,低剂量阿司匹林与任何类型的ICB风险增加无关,但使用低剂量阿司匹林超过1年,其与SAH风险明显降低相关。

原始出处:

Lucía Cea Soriano,et al. Low-dose aspirin and risk of intracranial bleeds An observational study in UK general practice.Neurology. 2017. http://dx.doi.org/10.1212/WNL.0000000000004694

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837368, encodeId=e1e9183e3685d, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue May 08 15:28:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043599, encodeId=e38c20435994d, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Mon Jul 02 17:28:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971233, encodeId=7b4519e12335c, content=<a href='/topic/show?id=1104469e552' target=_blank style='color:#2F92EE;'>#小剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46975, encryptionId=1104469e552, topicName=小剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Sat Sep 01 12:28:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000155, encodeId=d9902000155da, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Feb 11 14:28:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523554, encodeId=57f91523554cf, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sat Nov 04 03:28:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258073, encodeId=1fb12580e334, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4mzqK7XHyH86ToibWNdzamnZozW6yiceXFib4QHq1lCOia34v7bgwXUIH1Rdnoqia2y6ibLX156v1xmicZw/0, createdBy=15891613430, createdName=xuexin53, createdTime=Thu Nov 02 13:12:41 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837368, encodeId=e1e9183e3685d, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue May 08 15:28:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043599, encodeId=e38c20435994d, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Mon Jul 02 17:28:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971233, encodeId=7b4519e12335c, content=<a href='/topic/show?id=1104469e552' target=_blank style='color:#2F92EE;'>#小剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46975, encryptionId=1104469e552, topicName=小剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Sat Sep 01 12:28:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000155, encodeId=d9902000155da, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Feb 11 14:28:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523554, encodeId=57f91523554cf, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sat Nov 04 03:28:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258073, encodeId=1fb12580e334, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4mzqK7XHyH86ToibWNdzamnZozW6yiceXFib4QHq1lCOia34v7bgwXUIH1Rdnoqia2y6ibLX156v1xmicZw/0, createdBy=15891613430, createdName=xuexin53, createdTime=Thu Nov 02 13:12:41 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
    2018-07-02 pyaili
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837368, encodeId=e1e9183e3685d, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue May 08 15:28:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043599, encodeId=e38c20435994d, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Mon Jul 02 17:28:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971233, encodeId=7b4519e12335c, content=<a href='/topic/show?id=1104469e552' target=_blank style='color:#2F92EE;'>#小剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46975, encryptionId=1104469e552, topicName=小剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Sat Sep 01 12:28:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000155, encodeId=d9902000155da, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Feb 11 14:28:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523554, encodeId=57f91523554cf, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sat Nov 04 03:28:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258073, encodeId=1fb12580e334, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4mzqK7XHyH86ToibWNdzamnZozW6yiceXFib4QHq1lCOia34v7bgwXUIH1Rdnoqia2y6ibLX156v1xmicZw/0, createdBy=15891613430, createdName=xuexin53, createdTime=Thu Nov 02 13:12:41 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837368, encodeId=e1e9183e3685d, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue May 08 15:28:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043599, encodeId=e38c20435994d, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Mon Jul 02 17:28:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971233, encodeId=7b4519e12335c, content=<a href='/topic/show?id=1104469e552' target=_blank style='color:#2F92EE;'>#小剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46975, encryptionId=1104469e552, topicName=小剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Sat Sep 01 12:28:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000155, encodeId=d9902000155da, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Feb 11 14:28:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523554, encodeId=57f91523554cf, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sat Nov 04 03:28:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258073, encodeId=1fb12580e334, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4mzqK7XHyH86ToibWNdzamnZozW6yiceXFib4QHq1lCOia34v7bgwXUIH1Rdnoqia2y6ibLX156v1xmicZw/0, createdBy=15891613430, createdName=xuexin53, createdTime=Thu Nov 02 13:12:41 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
    2018-02-11 yinhl1978
  5. [GetPortalCommentsPageByObjectIdResponse(id=1837368, encodeId=e1e9183e3685d, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue May 08 15:28:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043599, encodeId=e38c20435994d, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Mon Jul 02 17:28:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971233, encodeId=7b4519e12335c, content=<a href='/topic/show?id=1104469e552' target=_blank style='color:#2F92EE;'>#小剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46975, encryptionId=1104469e552, topicName=小剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Sat Sep 01 12:28:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000155, encodeId=d9902000155da, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Feb 11 14:28:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523554, encodeId=57f91523554cf, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sat Nov 04 03:28:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258073, encodeId=1fb12580e334, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4mzqK7XHyH86ToibWNdzamnZozW6yiceXFib4QHq1lCOia34v7bgwXUIH1Rdnoqia2y6ibLX156v1xmicZw/0, createdBy=15891613430, createdName=xuexin53, createdTime=Thu Nov 02 13:12:41 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1837368, encodeId=e1e9183e3685d, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue May 08 15:28:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043599, encodeId=e38c20435994d, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Mon Jul 02 17:28:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971233, encodeId=7b4519e12335c, content=<a href='/topic/show?id=1104469e552' target=_blank style='color:#2F92EE;'>#小剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46975, encryptionId=1104469e552, topicName=小剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Sat Sep 01 12:28:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000155, encodeId=d9902000155da, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Feb 11 14:28:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523554, encodeId=57f91523554cf, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sat Nov 04 03:28:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258073, encodeId=1fb12580e334, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4mzqK7XHyH86ToibWNdzamnZozW6yiceXFib4QHq1lCOia34v7bgwXUIH1Rdnoqia2y6ibLX156v1xmicZw/0, createdBy=15891613430, createdName=xuexin53, createdTime=Thu Nov 02 13:12:41 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
    2017-11-02 xuexin53

    学习

    0

相关资讯

纯干货:哪些人群需要使用小剂量阿司匹林?

(一)用于缺血性心血管病高危人群一级预防的建议   建议下列高危人群应用阿司匹林(75~100 mg/d)进行一级预防: 1.患有高血压但血压控制满意(<150/90mmHg),同时有下列情况之一者: ①年龄在50岁以上。 ②具有靶器官损害,包括血浆肌酐中度增高。 ③糖尿病。 2. 患有2型糖尿病,40岁以上,同时有心血管危险因素者: